Table 2.
Predicted annual ASCVD deaths prevented and additional cases of myopathy from statin use among participants aged 40–75 years with diabetes—NHANES 2005–2010
| Characteristic | Population with diabetes* (100 000) | Eligible population† (100 000) | Estimated annual ASCVD deaths | ASCVD deaths prevented (95% CI) | RCT-based additional cases of myopathy (95% CI)‡ | Population-based additional cases of myopathy (95% CI)§ |
|---|---|---|---|---|---|---|
| Total | 123.5 | 77.0 | 23 380 | 2514 (592 to 4142) | 482 (0 to 2239) | 11 801 (9251 to 14 916) |
| Women | 57.2 | 35.4 | 9150 | 973 (229 to 1602) | 221 (to 1029) | 2787 (1923 to 3878) |
| Age group | ||||||
| 40–49 | 10.3 | 8.6 | 410 | 59 (14 to 98) | 54 (0 to 249) | 675 (466 to 940) |
| 50–59 | 19.0 | 11.5 | 1930 | 213 (50 to 351) | 72 (0 to 335) | 908 (626 to 1263) |
| 60–69 | 16.5 | 8.6 | 3050 | 294 (69 to 485) | 54 (0 to 250) | 677 (467 to 943) |
| 70–75 | 11.3 | 6.7 | 3760 | 406 (95 to 668) | 42 (0 to 193) | 523 (361 to 727) |
| Race/ethnicity | ||||||
| Non-Hispanic white | 42.5 | 26.1 | 6660 | 707 (166 to 1164) | 163 (0 to 759) | 2055 (1418 to 2859) |
| Non-Hispanic black | 6.3 | 3.9 | 1660 | 178 (42 to 293) | 25 (0 to 114) | 309 (213 to 430) |
| Hispanic | 5.3 | 3.3 | 561 | 59 (14 to 98) | 21 (0 to 97) | 264 (182 to 367) |
| Men | 66.3 | 41.6 | 14 230 | 1542 (363 to 2540) | 260 (0 to 1210) | 9014 (7328 to 11 038) |
| Age group | ||||||
| 40–49 | 17.2 | 12.6 | 1600 | 209 (49 to 343) | 79 (0 to 367) | 2734 (2222 to 3348) |
| 50–59 | 258 | 17.2 | 5130 | 616 (145 to 1014) | 107 (0 to 499) | 3718 (3022 to 4552) |
| 60–69 | 16.6 | 8.2 | 4250 | 392 (92 to 646) | 51 (0 to 238) | 1775 (1443 to 2173) |
| 70–75 | 6.7 | 3.7 | 3240 | 325 (77 to 536) | 23 (0 to 105) | 781 (635 to 956) |
| Race/ethnicity | ||||||
| Non-Hispanic white | 49.7 | 31.0 | 10 950 | 1184 (278 to 1949) | 193 (0 to 899) | 6701 (5447 to 8205) |
| Non-Hispanic black | 6.4 | 4.1 | 1950 | 214 (50 to 352) | 25 (0 to 118) | 882 (717 to 1080) |
| Hispanic | 6.6 | 4.3 | 880 | 96 (23 to 158) | 27 (0 to 124) | 926 (753 to 1134) |
*Population = number of adults aged 40–75 years with diabetes in 100 000.
†Eligible population = number of adults aged 40–75 years with diabetes multiplied by (1-prevalence of current statin use).
‡The estimated excess number of myopathy cases was based on an meta-analysis of RCTs estimate of the excessive incidence of myopathy, 0.0628 per 1000 patient-years.7
§The estimated excess number of myopathy cases was based on a population-based cohort study with over 2 million patients.6 The excess incidence of myopathy per 1000 patient-years was 2.176 (95% CI 1.769 to 2.655) for men and 0.791 (95% CI 0.545 to 1.100) for women.
ASCVD, atherosclerotic cardiovascular diseases; NHANES, National Health and Nutrition Examination Survey; RCT, randomised clinical trial.